The Global Radiopharmaceuticals Market, valued at USD 5.2 billion in 2022, is projected to grow to USD 9.75 billion by 2030, reflecting a CAGR of 9.4% from 2023 to 2030. This market growth is driven by the increasing demand for non-invasive diagnostic procedures, a rising incidence of cancer, and advancements in nuclear medicine. Innovations, including novel radioisotopes and AI integration in imaging analysis, are enhancing diagnostic and therapeutic capabilities. PET and SPECT imaging methods dominate the market, while regulatory support from bodies like the FDA and EMA is streamlining the approval of new radiopharmaceuticals. The report identifies major players in the field and outlines trends such as the rise of personalized medicine and sustainability challenges in production. Future growth is expected to be fueled by ongoing investment and research in the sector.
Fri, 28 Feb 2025 11:02:41 GMT | PharmiWeb.com